For the discovery of human antibodies blocking ACE2 binding by the viral S protein through screening of libraries of billions of human antibodies and their further validation to move them towards clinical trials as an antiviral drug to fight COVID-19 directly.
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Sachdev SidhuResearch Location
CanadaLead Research Institution
University of TorontoResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnosticsResearch Subcategory
ImmunitySpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
For the discovery of human antibodies blocking ACE2 binding by the viral S protein through screening of libraries of billions of human antibodies and their further validation to move them towards clinical trials as an antiviral drug to fight COVID-19 directly.